UNC Center for AIDS Research

It's about a real-life response to AIDS - a fierce commitment to creating and translating knowledge that advances the fight against HIV & AIDS

Acknowledge the CFAR Request A Service
  • About
    • Center Overview
    • Resources
      • HIV Matters Podcast Series
      • Training Tools
      • Related Organizations & Websites
    • Acknowledge the CFAR
    • Contact Us
  • Cores & Services
    • Administrative
      • CFAR Office of Community Engagement (OCE)
    • Biostatistics
    • Clinical
    • Clinical Pharmacology/Analytical Chemistry
    • Developmental
    • HIV/STD Laboratory (formerly VIM)
    • International
    • Social & Behavioral Science
  • Working Groups
  • Membership
  • News & Events
    • CFAR News & Announcements
    • CFAR Newsletters
    • Events Calendar
    • Friday Morning Conference
    • CFAR-Wide Webinar Series
    • 2019 Scientific Symposium
    • 2019 NCCC Community Symposium

UNC to Test Injectable Long-Acting Implant to Prevent HIV

May 3, 2017

Researchers at the University of North Carolina at Chapel Hill have received a three-year, $1.8 million grant from the National Institutes of Health to develop a new implantable drug delivery system for long-lasting HIV-prevention.

Scientists in the UNC School of Medicine’s Division of Infectious Diseases and the UNC Eshelman School of Pharmacy are developing an injectable drug delivery system that forms an implant that steadily releases anti-HIV medication over long periods of time.

The injectable formulation includes an anti-HIV drug, a polymer and a solvent. The three-compound liquid will solidify once injected under the skin. As the polymer slowly degrades, the drug is released. Efficacy of the new formulation to prevent HIV transmission will be evaluated using state of the art pre-clinical models developed at UNC.

Currently, a once-daily pill exists to prevent HIV infection. However, adherence to this daily regimen can be challenging for some people.

“This long-acting injectable formulation could provide a discrete and efficient method to protect against HIV infection and improve adherence, which is one of the major challenges of oral pre-exposure prophylaxis, or PrEP,” said Rahima Benhabbour, Ph.D., assistant professor in the UNC Eshelman School of Pharmacy and one of the study’s co-principal investigators. “The formulation is adaptable to a number of drugs alone or in combination and can be fine tuned to meet a targeted release regimen.”

Read more here..

News aids, cfar, drug, hiv, infection, pharmacy, polymer, test, treat, treatment, unc

Recent Posts

  • NICHD Grant Award Enables Researchers To Address Reasons For Vertical Transmission of HIV in Malawi As the Country Pursues Elimination Goals: Integrated Educational Cores Represent the Best of Capacity Building with Malawian Health Leaders
  • Gut Microbiome Can Increase Risk, Severity of HIV, EBV Disease
  • UNC CFAR Biostatistics Core Director, Michael Hudgens appointed to lead Gillings School’s Department of Biostatistics
  • UNC CFAR’s HIV/STD Core Associate Director, De Paris Receives Grant to Study HIV Vaccination in Infant Disease Models
  • Highlights from the 2023 HPTN Annual Meeting

GET IN TOUCH

UNC Center for AIDS Research
Lineberger Cancer Center
Chapel Hill, NC 27599
Email: prema_menezes@med.unc.edu

Follow Us

CFAR User Login
small_blue_trans
© 2018-2023 UNC CFAR. All rights reserved. Website by AndiSites Inc.